NCT03735992 Mind-body Medicine for Patients With Malignant Hematological Diseases
| NCT ID | NCT03735992 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universität Duisburg-Essen |
| Condition | Hematologic Neoplasms |
| Study Type | INTERVENTIONAL |
| Enrollment | 94 participants |
| Start Date | 2017-09-06 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 94 participants in total. It began in 2017-09-06 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized controlled trial aims to investigate the effectiveness of a mind-body group program as a supprtivemanagement strategy for fatigue in patients with malignant hematological diseases.
Eligibility Criteria
Inclusion Criteria: * Patients with malignant hematological diseases in complete remission after primary chemotherapy and/or radiation * Physical and mental ability to attent 8 of 11 group units Exclusion Criteria: * Chemotherapy, radiation, or rehabilitation programm during the study period * Pregnancy * Participation in other studies with behavioral interventions during the study period
Contact & Investigator
Gustav Dobos, Prof. MD
STUDY DIRECTOR
Center for Integrative Medicine and Health, University Hospital Essen, University of Duisburg-Essen
Frequently Asked Questions
Who can join the NCT03735992 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hematologic Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03735992 currently recruiting?
Yes, NCT03735992 is actively recruiting participants. Contact the research team at holger.cramer@med.uni-tuebingen.de for enrollment information.
Where is the NCT03735992 trial being conducted?
This trial is being conducted at Stuttgart, Germany.
Who is sponsoring the NCT03735992 clinical trial?
NCT03735992 is sponsored by Universität Duisburg-Essen. The principal investigator is Gustav Dobos, Prof. MD at Center for Integrative Medicine and Health, University Hospital Essen, University of Duisburg-Essen. The trial plans to enroll 94 participants.